

The Journal of Physiology

<https://jp.msubmit.net>

JP-CT-2018-276729

Title: CrossTalk proposal: Blood flow pulsatility in left ventricular assist device patients is essential to maintain normal brain physiology

Authors: Eric Stohr
Barry McDonnell
Paolo Colombo
Joshua Willey

Author Conflict: No competing interests declared

Author Contribution: Eric Stohr: Conception or design of the work; Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work Barry McDonnell: Conception or design of the work; Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work Paolo Colombo: Conception or design of the work; Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work Joshua Willey: Conception or design of the work; Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work

Running Title: Arterial Pulsatility in LVAD

Dual Publication: Figure 1. Please see figure legend.

Funding: European Union Horizon 2020: Eric J Stohr, Barry J McDonnell, 705219

CrossTalk proposal:

Blood Flow Pulsatility in LVAD Patients is essential to Maintain Normal Brain Physiology

Eric J. Stöhr^{1,2}, Barry J. McDonnell², Paolo C. Colombo¹, Joshua Z. Willey³

¹*Department of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York City, NY 10032, USA; ejs2212@cumc.columbia.edu, pcc2001@cumc.columbia.edu*

²*School of Sport & Health Sciences, Cardiff Metropolitan University, Cardiff, CF5 2YB, United Kingdom, estohr@cardiffmet.ac.uk, bmcdonnell@cardiffmet.ac.uk*


³*Department of Neurology, Neurological Institute of New York, Columbia University Irving Medical Center, New York City, NY 10032, USA jzw2@cumc.columbia.edu*

Word count: 1307 (1170 without references)

Key words: heart failure, LVAD, pulsatility, blood pressure, blood flow

1 **Biographies**

2 **Eric J. Stöhr** trained in exercise science in Germany and
3 obtained his PhD in 2011 in human cardiovascular physiology in
4 the UK. After postdoctoral studies and appointment to faculty,
5 he was awarded a Marie Skłodowska-Curie Fellowship and



6 joined Columbia University Irving Medical Center in 2016 where he studies advanced heart
7 failure patients. His research aims at understanding the interaction between the heart muscle
8 dynamics and arterial function in health and disease. **Joshua Z. Willey** is a vascular neurologist
9 with a research interest in cerebrovascular physiology and disease with mechanical circulatory
10 support. He completed his MD, neurology training, and stroke/epidemiology fellowships all at
11 Columbia University Medical Center where he is now an Assistant Professor of Neurology.

12

13

14

15

16

17

18

19

20

21 For the first time in history, some humans live without a palpable pulse (Purohit *et al.*, 2018).
22 This remarkable physiology is the consequence of surgical implantation of a continuous-flow left
23 ventricular assist device (CF-LVAD) in patients with end-stage heart failure. This CF-LVAD
24 creates a low oscillatory blood flow profile in the aorta that results in significantly reduced
25 pulsatility in all arterial compartments (Castagna *et al.*, 2017, Figure 1A and 1B). Despite
26 remarkable gains in quality of life and longevity, complications that affect not only morbidity
27 such as gastrointestinal bleeding, but also mortality such as strokes, are still prevalent in CF-
28 LVAD patients. Low pulsatility has been proposed as a major culprit in contributing to these
29 adverse events (Mancini & Colombo, 2015; Goldstein *et al.*, 2018). In this CrossTalk, we present
30 the current arguments in favour of maintaining an appropriate amount of arterial pulsatility, in
31 particular in the cerebral circulation, to lower risk in these patients.

32

33 **Cerebral microcirculation and O₂ kinetics**

34 A macro-circulatory link between cardiac output, aortic stiffness and arterial pulsatility with the
35 brain is well-established (Mitchell *et al.*, 2011; Jefferson *et al.*, 2015). At the level of the
36 microcirculation, it is thought that the healthy circulation already presents with absence of pulse
37 pressure (O'Rourke & Hashimoto, 2007), and hence CF-LVADs would not create a different
38 environment for gas exchange from normal physiology. However, even in healthy individuals,
39 measurements of arteriolar haemodynamics have revealed pulsatile patterns (Rappaport *et al.*,
40 1959; Shore, 2000). An important implication is that a pulsatile velocity profile entails that
41 cerebral transit time (CTT) slows in the diastolic phase and facilitates the oxygen gradient for
42 gas exchange. In CF-LVAD patients, the increased diastolic blood velocity may result in an
43 overall elevated mean blood velocity (Brassard *et al.*, 2011; Castagna *et al.*, 2017, and Figure

44 1B), thereby impairing oxygen kinetics (Wardlaw *et al.*, 2002). However, data on absolute blood
45 velocities are scarce, or their interpretation currently lacks confidence because the assessment of
46 cerebral blood velocities, even in the pre-arteriolar circulation, has typically not been performed
47 with the necessary angle correction of the Doppler signal. Whatever the real O₂ kinetics in CF-
48 LVAD, it is known that cerebral blood flow is also regulated for reasons other than O₂
49 requirements (Mintun *et al.*, 2001). Thus, the low pulsatile, diastolic-dominant haemodynamics
50 of CF-LVAD impact on cerebral artery properties beyond gas exchange, as discussed in the
51 following paragraphs.

52

53 **Cerebral auto-regulation**

54 Cerebral autoregulation has been proposed to take effect across a more narrow range of perfusion
55 pressure than previously thought (Willie *et al.*, 2014). Consequently, the low systolic blood
56 pressure and low-to-normal mean arterial pressure coupled with a normal cardiac output mean
57 that CF-LVAD patients may find themselves on an unusual point of the perfusion-cerebral blood
58 flow (CBF) curve, with high flow into a low-resistance cerebral circulation (Cornwell *et al.*,
59 2014). The high-flow low-resistance is directly caused by the low-pulsatile haemodynamics of
60 CF-LVAD. Notwithstanding, cerebral auto-regulation may be preserved in CF-LVAD patients
61 (Ono *et al.*, 2012; Cornwell *et al.*, 2014), independent of end-tidal CO₂ concentrations (Cornwell
62 *et al.*, 2014). However, some remaining differences to normal brain physiology can be noted. For
63 instance, the variance in CBF was most similar between healthy individuals and CF-LVAD
64 patients, while patients with pulsatile devices responded significantly differently to a sit-to-stand
65 challenge (Cornwell *et al.*, 2014). These intriguing findings may indicate a meaningful role of
66 added pulsatility in the context of LVAD and justify a more detailed investigation into the

67 dynamics of perfusion pressure (i.e. pulse pressure) and cerebral autoregulation in the setting of
68 low absolute pressures (Ono *et al.*, 2017). Rather than being disturbed itself, the maintained
69 cerebral autoregulation in CF-LVAD may cause a reduction in pulsatility since the total flow is
70 already high.

71

72 **Endothelial function, bleeding and aortic stiffness**

73 Pulsatility of *flow* against the cyclical stretch of the arterial wall is a critical contributor to
74 endothelial production of nitric oxide and cardiovascular health (Hahn & Schwartz, 2009). The
75 high occurrence of bleeding events such as GI bleeding and haemorrhagic strokes indicate a
76 primary problem with endothelial integrity. A recent study confirms elegantly that a staggering
77 proportion of LVAD patients have cortical microbleeds in a pattern similar to cerebral amyloid
78 angiopathy, a condition with high rates of arteriolar fragility (Yoshioka *et al.*, 2017).
79 Furthermore, reduced pulsatility appears responsible for the marked reduction in endothelial
80 nitric oxide bioavailability in CF-LVAD patients when compared to those on support with
81 pulsatile device (Witman *et al.*, 2015). While shear rate has not been measured in the cerebral
82 circulation of CF-LVAD patients, it is conceivable that it would be higher than normal in the
83 diastolic phase of the cardiac cycle, a circumstance that, when present in the carotid artery, has
84 been associated with adverse cerebral events in non-LVAD populations (Mutsaerts *et al.*, 2011).
85 In addition, the high diastolic flow likely contributes to increased arterial stiffness observed in
86 CF-LVAD patients by markedly attenuating the normal systolic-diastolic stretch and recoil cycle
87 (Ambardekar *et al.*, 2015; Patel *et al.*, 2017). It is important to underline that in pulsatile
88 circulations, aortic stiffness increases the transmission of pulsatility to the periphery, and, if
89 exceeding normal pulsatility, is detrimental to the brain and other end-organs (Webb *et al.*,

90 2012). Paradoxically, this means that the reduced Windkessel effect in CF-LVAD patients
91 because of the larger diastolic flow and increased aortic stiffness might be beneficial in some
92 individuals via a mild augmentation of pulsatile dynamics transmitted to the periphery, which
93 would otherwise be harmful to end-organs. Finally, elegant insight into bleeding-associated
94 complications in CF-LVAD - which may include blood-brain-barrier disruption and cortical
95 microbleeds - has been provided by Vincent *et al.* (2018). These authors showed that the loss of
96 von Willebrand-Factor from the high shear forces within the mechanical device was, at least in
97 part, offset by increased arterial pulsatility, which promoted new vWF release from the
98 endothelium. Hence, mild increases in arterial pulsatility may mitigate bleeding risk in CF-
99 LVAD patients.

100

101 **Additional considerations**

102 Two common misconceptions related to CF-LVAD physiology, and specifically pulsatility,
103 deserve attention. First, it is commonly assumed that CF-LVADs should produce perfectly
104 continuous flow if the aortic valve does not open (Floras *et al.*, 2015). This assumption overlooks
105 the role of fluctuations of the intra-ventricular pressure within each cardiac cycle. The resulting
106 changes in pressure-gradient between LVAD inflow and aortic outflow graft creates variability
107 in pump flow between systole and diastole and thereby generates arterial pulsatility (Khalil *et al.*,
108 2008; Pagani, 2008).

109 Second, the absolute blood volume in relation to the pulsatility is often ignored. Although
110 pulsatility is typically reduced with a higher LVAD speed, the concomitant increase in cardiac
111 output may have significant effects beyond that of reduced pulsatility. Acutely, a larger flow into
112 the cerebral circulation will result in increased resistance and possibly higher pressure. In any

113 case, it is important to consider cardiac output in relation to the local peripheral vasodilation and
114 vasoconstriction. Studies examining the effects of pulsatile cardiopulmonary bypass reported that
115 the number of perfused vessels in the microcirculation was increased compared with a
116 continuous-flow circulation (O'Neil *et al.*, 2012; Inamori *et al.*, 2013). Importantly, the authors
117 also reported, “pulsatility resulted in a reduction in the prevalence of pathologic hyper-
118 dynamically perfused vessels” (O'Neil *et al.*, 2012). This observation strongly supports a role of
119 pulsatility independent of blood volume since the latter was not significantly different between
120 pulsatile and continuous-flow bypass.

121 One final comment relates to the newest generation of CF-LVADs. Whether the recent
122 improvements in outcomes, including the reduced incidence of stroke in HeartMate 3 patients
123 (Mehra *et al.*, 2018), can be attributed to the added pulsatility and the greater load-sensitivity of
124 the device itself – and hence greater intrinsic pulsatile oscillation within one cardiac cycle
125 (Pagani, 2008) – remains to be confirmed. Collectively, the presented evidence suggests that
126 CF-LVAD patients are currently not exposed to a normal brain physiology and that mild
127 increases in arterial pulsatility may be beneficial.

128

129 **Acknowledgements**

130 This project has received funding from the European Union’s Horizon 2020 research and
131 innovation programme under the Marie Skłodowska-Curie grant agreement No 705219.



132

133

134

135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162

References

Ambardekar AV, Hunter KS, Babu AN, Tudor RM, Dodson RB & Lindenfeld J. (2015). Changes in Aortic Wall Structure, Composition, and Stiffness With Continuous-Flow Left Ventricular Assist Devices: A Pilot Study. *Circ Heart Fail* **8**, 944-952.

Brassard P, Jensen AS, Nordsborg N, Gustafsson F, Moller JE, Hassager C, Boesgaard S, Hansen PB, Olsen PS, Sander K, Secher NH & Madsen PL. (2011). Central and peripheral blood flow during exercise with a continuous-flow left ventricular assist device: constant versus increasing pump speed: a pilot study. *Circ Heart Fail* **4**, 554-560.

Castagna F, Stöhr EJ, Pinsino A, Cockcroft JR, Willey J, Reshad Garan A, Topkara VK, Colombo PC, Yuzefpolskaya M & McDonnell BJ. (2017). The Unique Blood Pressures and Pulsatility of LVAD Patients: Current Challenges and Future Opportunities. *Curr Hypertens Rep* **19**, 85.

Cornwell WK, 3rd, Tarumi T, Aengevaeren VL, Ayers C, Divanji P, Fu Q, Palmer D, Drazner MH, Meyer DM, Bethea BT, Hastings JL, Fujimoto N, Shibata S, Zhang R, Markham DW & Levine BD. (2014). Effect of pulsatile and nonpulsatile flow on cerebral perfusion in patients with left ventricular assist devices. *J Heart Lung Transplant* **33**, 1295-1303.

Floras JS, Rao V & Billia F. (2015). To Pulse or Not to Pulse, Is That the Question? *Circulation* **132**, 2293-2296.

Goldstein DJ, Mehra MR, Naka Y, Salerno C, Uriel N, Dean D, Itoh A, Pagani FD, Skipper ER, Bhat G, Raval N, Bruckner BA, Estep JD, Cogswell R, Milano C, Fendelander L, O'Connell JB, Cleveland J & Investigators M. (2018). Impact of age, sex, therapeutic

163 intent, race and severity of advanced heart failure on short-term principal outcomes in the
164 MOMENTUM 3 trial. *J Heart Lung Transplant* **37**, 7-14.

165
166 Hahn C & Schwartz MA. (2009). Mechanotransduction in vascular physiology and
167 atherogenesis. *Nat Rev Mol Cell Biol* **10**, 53-62.

168
169 Inamori S, Shirai M, Yahagi N, Pearson JT, Fujii Y, Umetani K, Kobayashi Y, Okura Y,
170 Yakehiro M & Minamiyama M. (2013). A comparative study of cerebral
171 microcirculation during pulsatile and nonpulsatile selective cerebral perfusion:
172 assessment by synchrotron radiation microangiography. *ASAIO J* **59**, 374-379.

173
174 Jefferson AL, Beiser AS, Himali JJ, Seshadri S, O'Donnell CJ, Manning WJ, Wolf PA, Au R &
175 Benjamin EJ. (2015). Low cardiac index is associated with incident dementia and
176 Alzheimer disease: the Framingham Heart Study. *Circulation* **131**, 1333-1339.

177
178 Khalil HA, Cohn WE, Metcalfe RW & Frazier OH. (2008). Preload sensitivity of the Jarvik 2000
179 and HeartMate II left ventricular assist devices. *ASAIO J* **54**, 245-248.

180
181 Mancini D & Colombo PC. (2015). Left Ventricular Assist Devices: A Rapidly Evolving
182 Alternative to Transplant. *J Am Coll Cardiol* **65**, 2542-2555.

183
184 Mehra MR, Goldstein DJ, Uriel N, Cleveland JC, Jr., Yuzefpolskaya M, Salerno C, Walsh MN,
185 Milano CA, Patel CB, Ewald GA, Itoh A, Dean D, Krishnamoorthy A, Cotts WG,
186 Tatooles AJ, Jorde UP, Bruckner BA, Estep JD, Jeevanandam V, Sayer G, Horstmanshof
187 D, Long JW, Gulati S, Skipper ER, O'Connell JB, Heatley G, Sood P, Naka Y &
188 Investigators M. (2018). Two-Year Outcomes with a Magnetically Levitated Cardiac
189 Pump in Heart Failure. *N Engl J Med* **378**, 1386-1395.

190

191 Mintun MA, Lundstrom BN, Snyder AZ, Vlassenko AG, Shulman GL & Raichle ME. (2001).
192 Blood flow and oxygen delivery to human brain during functional activity: theoretical
193 modeling and experimental data. *Proc Natl Acad Sci U S A* **98**, 6859-6864.

194

195 Mitchell GF, van Buchem MA, Sigurdsson S, Gotal JD, Jonsdottir MK, Kjartansson O, Garcia
196 M, Aspelund T, Harris TB, Gudnason V & Launer LJ. (2011). Arterial stiffness, pressure
197 and flow pulsatility and brain structure and function: the Age, Gene/Environment
198 Susceptibility--Reykjavik study. *Brain* **134**, 3398-3407.

199

200 Mutsaerts HJ, Palm-Meinders IH, de Craen AJ, Reiber JH, Blauw GJ, van Buchem MA, van der
201 Grond J, Box FM & Group PS. (2011). Diastolic carotid artery wall shear stress is
202 associated with cerebral infarcts and periventricular white matter lesions. *Stroke* **42**,
203 3497-3501.

204

205 O'Neil MP, Fleming JC, Badhwar A & Guo LR. (2012). Pulsatile versus nonpulsatile flow
206 during cardiopulmonary bypass: microcirculatory and systemic effects. *Ann Thorac Surg*
207 **94**, 2046-2053.

208

209 O'Rourke MF & Hashimoto J. (2007). Mechanical factors in arterial aging: a clinical perspective.
210 *J Am Coll Cardiol* **50**, 1-13.

211

212 Ono M, Joshi B, Brady K, Easley RB, Kibler K, Conte J, Shah A, Russell SD & Hogue CW.
213 (2012). Cerebral blood flow autoregulation is preserved after continuous-flow left
214 ventricular assist device implantation. *J Cardiothorac Vasc Anesth* **26**, 1022-1028.

215

216 Ono M, Singh SK, Kibler KK, Easley BR, Frazier OH & Brady KM. (2017). How Does the
217 Pulse Pressure Impact on Cerebral Autoregulation Between Axial and Centrifugal
218 LVAD? *The Journal of Heart and Lung Transplantation* **36**, S194.

219

220 Pagani FD. (2008). Continuous-flow rotary left ventricular assist devices with "3rd generation"
221 design. *Semin Thorac Cardiovasc Surg* **20**, 255-263.

222

223 Patel AC, Dodson RB, Cornwell WK, 3rd, Hunter KS, Cleveland JC, Jr., Brieke A, Lindenfeld J
224 & Ambardekar AV. (2017). Dynamic Changes in Aortic Vascular Stiffness in Patients
225 Bridged to Transplant With Continuous-Flow Left Ventricular Assist Devices. *JACC*
226 *Heart Fail* **5**, 449-459.

227

228 Purohit SN, Cornwell WK, 3rd, Pal JD, Lindenfeld J & Ambardekar AV. (2018). Living Without
229 a Pulse: The Vascular Implications of Continuous-Flow Left Ventricular Assist Devices.
230 *Circ Heart Fail* **11**, e004670.

231

232 Rappaport MB, Bloch EH & Irwin JW. (1959). A Manometer for Measuring Dynamic Pressures
233 in the Microvascular System. *Journal of Applied Physiology* **14**, 651-655.

234

235 Shore AC. (2000). Capillaroscopy and the measurement of capillary pressure. *Br J Clin*
236 *Pharmacol* **50**, 501-513.

237

238 Vincent F, Rauch A, Loobuyck V, Robin E, Nix C, Vincentelli A, Smadja DM, Leprince P,
239 Amour J, Lemesle G, Spillemaeker H, Debry N, Latremouille C, Jansen P, Capel A,
240 Moussa M, Rouse N, Schurtz G, Delhay C, Paris C, Jeanpierre E, Dupont A, Corseaux
241 D, Rosa M, Sottejeau Y, Barth S, Mourran C, Gomane V, Coisne A, Richardson M,
242 Caron C, Preda C, Ung A, Carpentier A, Hubert T, Denis C, Staels B, Lenting PJ, Van
243 Belle E & Susen S. (2018). Arterial Pulsatility and Circulating von Willebrand Factor in
244 Patients on Mechanical Circulatory Support. *J Am Coll Cardiol* **71**, 2106-2118.

245

246 Wardlaw JM, Dennis MS, Merrick MV & Warlow CP. (2002). Relationship between absolute
247 mean cerebral transit time and absolute mean flow velocity on transcranial Doppler
248 ultrasound after ischemic stroke. *J Neuroimaging* **12**, 104-111.

249
250 Webb AJ, Simoni M, Mazzucco S, Kuker W, Schulz U & Rothwell PM. (2012). Increased
251 cerebral arterial pulsatility in patients with leukoaraiosis: arterial stiffness enhances
252 transmission of aortic pulsatility. *Stroke* **43**, 2631-2636.

253
254 Willie CK, Tzeng YC, Fisher JA & Ainslie PN. (2014). Integrative regulation of human brain
255 blood flow. *J Physiol* **592**, 841-859.

256
257 Witman MA, Garten RS, Gifford JR, Groot HJ, Trinity JD, Stehlik J, Nativi JN, Selzman CH,
258 Drakos SG & Richardson RS. (2015). Further Peripheral Vascular Dysfunction in Heart
259 Failure Patients With a Continuous-Flow Left Ventricular Assist Device: The Role of
260 Pulsatility. *JACC Heart Fail* **3**, 703-711.

261
262 Yoshioka D, Okazaki S, Toda K, Murase S, Saito S, Domae K, Miyagawa S, Yoshikawa Y,
263 Daimon T, Sakaguchi M & Sawa Y. (2017). Prevalence of Cerebral Microbleeds in
264 Patients With Continuous-Flow Left Ventricular Assist Devices. *J Am Heart Assoc* **6**.

265

266

267

268

269


270

271

272 **Figures**

273

274 **Figure 1.** The schematic of the continuous-flow left ventricular assist device (CF-LVAD) shows
275 the inflow cannula connection to the LV apex and the anastomosis of the outflow cannula to
276 the ascending aorta (A). Representative pressure and flow profiles in the carotid artery and
277 middle cerebral artery (*highlighted in yellow*) show the significant differences in pulsatility (B).
278 LVAD schematic reproduced with permission from St Jude Medical. (B) was modified from
279 Castagna *et al.* (2017) and was originally distributed under the terms of the Creative Commons
280 Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>).



B)

<i>Circulation</i>	Blood pressure	Common carotid artery	Middle cerebral artery
Healthy			
HeartMate II (moderate pulsatility)			
HeartMate II (low pulsatility)			
Jarvik 2000			
HeartMate 3			